Topline results from REZILIENT3 show zipalertinib plus chemotherapy significantly improves progression-free survival in EGFR exon 20 insertion NSCLC. The Independent Data Monitoring Committee recommended unblinding, with US regulatory discussions planned, potentially expediting approval for first-line use. The news could lift Cullinan Therapeutics’ pipeline valuation and catalyze partnership or milestone opportunities for CGEM.
New data from REZILIENT2 study on zipalertinib was shared. Intracranial objective response rate was 31.3% in evaluated patients. Safety profile was acceptable with no new safety signals reported. CGEM stock rose 4.96% to $7.77 after data announcement. Data to be presented at ESMO Congress 2025 in February.
